Is Prestige Consumer Healthcare (PBH) overvalued or fairly valued?

MarketChacha shows Prestige Consumer Healthcare's valuation in context — a trailing P/E of about 15.4, a forward P/E of about 10.3, a price-to-book of about 1.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Prestige Consumer Healthcare's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.86×) from reported figures — education, not a rating.

What is Prestige Consumer Healthcare's revenue?

Prestige Consumer Healthcare reported revenue of $1.1B for FY2026, with net profit of $190.3M, per official filings.

What is the share price of Prestige Consumer Healthcare (PBH)?

Prestige Consumer Healthcare last traded at $52.26 (-0.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Prestige Consumer Healthcare

PBH · NYSE · Healthcare · United States

Snapshot

TickerPBH

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees890

HeadquartersTarrytown, United States

Websitewww.prestigebrands.com

Filings tracked16

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Who owns it

Insiders1.4%
Institutions98.6%
Public & other0.0%

438 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.53%
Ariel Investments, LLC10.28%
Vanguard Portfolio Management LLC5.96%
Dimensional Fund Advisors LP5.62%
Fuller & Thaler Asset Management Inc.4.92%
Vanguard Capital Management LLC4.51%
State Street Corporation4.47%
Brandes Investment Partners L.P.4.33%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.86×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend-7.3% → 17.5%

Margin has expanded by about 24.8 points — the business is getting more profitable.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $353.1M · EPS 1.24

Est. earnings growth +8.9%

Next fiscal year

Rev $1.4B · EPS 5.08

Est. earnings growth +11.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$1.1B

Net margin

17.5%

ROE

10.1%

Revenue CAGR (3y)

-1.2%

EPS (FY2026)

3.91

Net profit (FY2026)

$190.3M

Ask MarketChacha about PBH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$1.1B	$190.3M	3.91	17.5%	10.1%
FY2025	$1.1B	$214.6M	4.29	18.9%	11.7%
FY2024	$1.1B	$209.3M	4.17	18.6%	12.6%
FY2023	$1.1B	$-82.3M	-1.65	-7.3%	-5.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$265.7M	$29.2M	0.61	11.0%
2025Q4	$283.4M	$46.7M	0.97	16.5%
2025Q3	$274.1M	$42.2M	0.86	15.4%
2025Q2	$249.5M	$47.5M	0.95	19.0%
2024Q4	$290.3M	$61.0M	1.22	21.0%
2024Q3	$283.8M	$54.4M	1.09	19.2%
2024Q2	$267.1M	$49.1M	0.98	18.4%
2023Q4	$282.7M	$53.0M	1.06	18.8%
2023Q3	$286.3M	$53.6M	1.07	18.7%
2023Q2	$279.3M	$53.3M	1.06	19.1%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Material agreement, Material financial obligation, Exhibits
SEC7/15/2026material
8-K/A — Exhibits
SEC7/9/2026
8-K — Material agreement, Material financial obligation, Reg FD disclosure, Exhibits
SEC7/6/2026material
8-K/A — Exhibits
SEC6/30/2026
8-K — Material agreement, Completion of acquisition/disposition, Material financial obligation, Other events, Exhibits
SEC6/16/2026material
10-K filing
SEC5/14/2026
8-K — Material agreement, Results of operations, Reg FD disclosure, Exhibits
SEC5/13/2026material
8-K — Material agreement, Reg FD disclosure, Other events, Exhibits
SEC3/20/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/5/2026material
10-Q filing
SEC2/5/2026

2025

8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Material agreement, Results of operations, Reg FD disclosure, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.